{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:45:03Z","timestamp":1765295103114,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011665","name":"Deanship of Scientific Research, King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jchromb.2020.122015","type":"journal-article","created":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T11:19:12Z","timestamp":1580555952000},"page":"122015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A rapid, simple and highly sensitive UPLC-MS\/MS method for quantitation of pimavanserin in plasma and tissues: Application to pharmacokinetics and brain uptake studies in mice"],"prefix":"10.1016","volume":"1143","author":[{"given":"Essam","family":"Ezzeldin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzaffar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousif A.","family":"Asiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azza A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toqa","family":"El-Nahhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2020.122015_b0005","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/mds.22132","article-title":"Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: positive impact on long-term worsening","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jchromb.2020.122015_b0010","doi-asserted-by":"crossref","first-page":"262","DOI":"10.9740\/mhc.2017.11.262","article-title":"Treatment of psychotic symptoms in patients with Parkinson disease","volume":"7","author":"Chen","year":"2018","journal-title":"Ment. Health Clin."},{"key":"10.1016\/j.jchromb.2020.122015_b0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors","volume":"123","author":"F\u00e9nelon","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.jchromb.2020.122015_b0020","doi-asserted-by":"crossref","first-page":"e00639","DOI":"10.1002\/brb3.639","article-title":"Atypical antipsychotic therapy in Parkinson's disease psychosis: a retrospective study","volume":"7","author":"Yuan","year":"2017","journal-title":"Brain Behav."},{"key":"10.1016\/j.jchromb.2020.122015_b0025","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archneur.1996.00550120077019","article-title":"Visual hallucinations associated with Parkinson disease","volume":"53","author":"Sanchez-Ramos","year":"1996","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jchromb.2020.122015_b0030","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/WNF.0000000000000296","article-title":"Pimavanserin for psychotic symptoms in people with parkinsonism: a second chart review","volume":"41","author":"Friedman","year":"2018","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jchromb.2020.122015_b0035","first-page":"16","article-title":"Pimavanserin: a novel drug approved to treat Parkinson's disease psychosis","volume":"15","author":"Kitten","year":"2018","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.jchromb.2020.122015_b0040","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s10072-018-3500-5","article-title":"Pimavanserin use in a movement disorders clinic: a single-center experience","volume":"39","author":"Mahajan","year":"2018","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jchromb.2020.122015_b0045","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jagp.2018.06.001","article-title":"Perspective on pimavanserin and the SAPS-PD: novel scale development as a means to FDA approval","volume":"26","author":"Schubmeh","year":"2018","journal-title":"Am. J. Geriatr. Psychiatry."},{"key":"10.1016\/j.jchromb.2020.122015_b0050","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(18)31002-X","article-title":"Pimavanserin evaluated by the FDA","volume":"391","author":"Webster","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jchromb.2020.122015_b0055","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/17512433.2017.1369405","article-title":"Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis","volume":"10","author":"Kianirad","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2020.122015_b0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11940-013-0281-2","article-title":"Treatment of psychosis and dementia in Parkinson's disease","volume":"16","author":"Goldman","year":"2014","journal-title":"Curr. Treat. Opt. Neurol."},{"key":"10.1016\/j.jchromb.2020.122015_b0065","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/0091270007299431","article-title":"Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers","volume":"47","author":"Vanover","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2020.122015_b0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/1060028017693029","article-title":"Pimavanserin: a novel antipsychotic for Parkinson's disease psychosis","volume":"51","author":"Bozymski","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jchromb.2020.122015_b0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1212\/CPJ.0000000000000342","article-title":"Pimavanserin: a novel therapeutic option for Parkinson disease psychosis","volume":"7","author":"Hawkins","year":"2017","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.jchromb.2020.122015_b0080","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/2045125317721662","article-title":"Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature","volume":"7","author":"Meid","year":"2017","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jchromb.2020.122015_b0085","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145707007869","article-title":"PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain","volume":"11","author":"Nordstrom","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jchromb.2020.122015_b0090","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.4088\/JCP.16r11119","article-title":"The US food and drug administration's perspective on the new antipsychotic pimavanserin","volume":"78","author":"Mathis","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jchromb.2020.122015_b0095","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl) carbamide (2R, 3R)-dihydroxybutanedioate (2:1) (ACP -103), a novel 5-hydroxytryptamine (2A) receptor inverse agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jchromb.2020.122015_b0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1517\/17425247.2016.1092519","article-title":"Brain-blood ratio: implications in brain drug delivery","volume":"13","author":"Kulkarni","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jchromb.2020.122015_b0105","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jpba.2017.11.008","article-title":"Pharmacokinetics and brain uptake study of novel AMPA receptor antagonist perampanel in SD rats using a validated UHPLC-QTOF-MS method","volume":"149","author":"Paul","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"6","key":"10.1016\/j.jchromb.2020.122015_b0110","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jpha.2017.07.004","article-title":"Development of a UPLC-MS\/MS method for determination of pimavanserin tartrate in rat plasma: application to a pharmacokinetic study","volume":"7","author":"Wang","year":"2017","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jchromb.2020.122015_b0115","unstructured":"European Medicines Agency, Guideline on Bioanalytical Method Validation, 2012. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf."},{"key":"10.1016\/j.jchromb.2020.122015_b0120","unstructured":"Guidance for Industry on Bioanalytical Method Validation, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD, 2001. https:\/\/www.fda.gov\/downloads\/Drugs\/Guidance\/ucm070107.pdf (accessed 01.03.2018)."},{"key":"10.1016\/j.jchromb.2020.122015_b0125","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1016\/j.bmcl.2006.06.053","article-title":"Correlation between brain\/plasma ratios and efficacy in neuropathic pain models of selective metabotropic glutamate receptor 1 antagonists","volume":"16","author":"Zheng","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jchromb.2020.122015_b0130","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/sj.jcbfm.9600415","article-title":"A direct method for measuring mouse capillary cortical blood volume using multiphoton laser scanning microscopy","volume":"27","author":"V\u00e9rant","year":"2007","journal-title":"J. Cereb. Blood Flow Metab."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023219315843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023219315843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T22:59:49Z","timestamp":1761605989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023219315843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":26,"alternative-id":["S1570023219315843"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.122015","relation":{},"ISSN":["1570-0232"],"issn-type":[{"type":"print","value":"1570-0232"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A rapid, simple and highly sensitive UPLC-MS\/MS method for quantitation of pimavanserin in plasma and tissues: Application to pharmacokinetics and brain uptake studies in mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.122015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122015"}}